Cancers, Vol. 11, Pages 1667: A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
Cancers, Vol. 11, Pages 1667: A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
Cancers doi: 10.3390/cancers11111667
Authors:
So Young Yoo
Narayanasamy Badrinath
Hye Lim Lee
Jeong Heo
Dae-Hwan Kang
While oncolytic vaccinia virus-based therapy has shown promising results for uncured patients with cancer, its effects on cholangiocarcinoma (CCA) remain unclear. Here, we evaluated the anti-cancer activity of the cancer-favoring oncolytic vaccinia virus (CVV), which was recognized as a promising therapy for stem cell-like colon cancer cells (SCCs) and metastatic hepatocellular carcinoma (HCC) in previous studies. CCA presents major challenges, such as clinical complexity, stem cell cancer characteristics, a high refractory rate, resistance to conventional therapy, and a dismal prognosis. In the present study, we confirmed the oncolytic activity of the CVV in CCA with a slightly alkaline microenvironment (pH 7–8), in which the CVV was stable and highly effective at infecting CCA. Taken together, our findings suggest that CVV-based therapy is highly suitable for the treatment of CCA.
Source: Cancers - Category: Cancer & Oncology Authors: So Young Yoo Narayanasamy Badrinath Hye Lim Lee Jeong Heo Dae-Hwan Kang Tags: Communication Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Colon Cancer | Colorectal Cancer | Hepatocellular Carcinoma | Liver Cancer | Stem Cell Therapy | Stem Cells | Study